

### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## Molecular Diagnostics at the Point of Care

by Application, Technology, Place, Product and  
Country with COVID-19 POC Breakout

+ Executive Guides and Customization 2022 to 2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides .....	25
1.1	Molecular Diagnostics at the Point of Care - Strategic Situation Analysis and Impact of COVID-19. ....	26
1.2	Guide for Executives, Marketing, Sales and Business Development Staff .....	28
1.3	Guide for Management Consultants and Investment Advisors .....	29
2	Introduction and Market Definition .....	30
2.1	What are Molecular Diagnostics at the Point of Care? .....	31
2.2	The Diagnostics Revolution.....	33
2.3	Market Definition .....	35
2.3.1	Revenues.....	35
2.4	Methodology.....	37
2.4.1	Authors .....	37
2.4.2	Sources .....	37
2.5	Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic .....	38
2.5.1	Global Healthcare Spending .....	38
2.5.2	Spending on Diagnostics .....	40
2.5.3	Important Role of Insurance for Diagnostics .....	41
3	The Infectious Diseases – Market Analysis by Disease .....	42
3.1	HIV - Human Immunodeficiency Virus (AIDS) .....	43
3.1.1	Virology .....	43

3.1.1.1	Classification .....	43
3.1.1.2	Structure and genome.....	44
3.1.1.3	Tropism.....	47
3.1.1.4	Replication cycle.....	49
3.1.1.5	Genetic variability .....	55
3.1.2	Diagnosis .....	56
3.1.3	Testing.....	58
3.1.3.1	Antibody tests .....	58
3.1.3.2	Point of Care Tests (POCT) .....	61
3.1.3.3	Antigen Tests .....	64
3.1.3.4	Nucleic acid-based tests (NAT) .....	64
3.1.3.5	Other tests used in HIV treatment.....	65
3.1.4	Market Opportunity Analysis .....	66
3.2	HBV – Hepatitis B.....	71
3.2.1	Virology .....	72
3.2.1.1	Genome .....	73
3.2.1.2	Pathogenesis.....	74
3.2.1.3	Hepatitis B virus replication .....	74
3.2.1.4	Serotypes and genotypes.....	75
3.2.2	Mechanisms.....	75
3.2.3	Diagnosis .....	76
3.2.4	Market Opportunity Analysis .....	77
3.3	HCV – Hepatitis C.....	79
3.3.1	Taxonomy.....	80

3.3.2	Structure .....	81
3.3.2.1	Genome .....	81
3.3.3	Molecular biology .....	82
3.3.4	Replication.....	84
3.3.5	Genotypes .....	85
3.3.5.1	Clinical importance.....	86
3.3.6	Market Opportunity Analysis .....	86
3.4	HPV - Human papillomavirus.....	88
3.4.1	Virology .....	90
3.4.1.1	E6/E7 proteins.....	90
3.4.1.2	Role in cancer.....	90
3.4.1.3	E2 research.....	91
3.4.1.4	Latency period .....	93
3.4.1.5	Clearance .....	93
3.4.2	Diagnosis .....	93
3.4.2.1	Cervical testing .....	93
3.4.2.2	Oral testing .....	95
3.4.2.3	Testing men .....	95
3.4.2.4	Other testing .....	97
3.4.3	Market Opportunity Analysis .....	97
3.5	Influenza.....	103
3.5.1	Virology .....	105
3.5.1.1	Types of virus .....	105
3.5.1.2	Influenzavirus A .....	105

3.5.1.3	Influenzavirus B.....	106
3.5.1.4	Influenzavirus C .....	106
3.5.1.5	Structure, properties, and subtype nomenclature .....	106
3.5.1.6	Replication .....	108
3.5.2	Testing.....	110
3.5.2.1	Advantages/Disadvantages of Molecular Assays.....	112
3.5.3	Market Opportunity Analysis .....	113
3.6	CTGC - Chlamydia/Gonorhea .....	123
3.6.1	Gonorrhea .....	123
3.6.1.1	Diagnosis .....	124
3.6.1.2	Screening .....	124
3.6.2	Chlamydia .....	124
3.6.2.1	Diagnosis .....	125
3.6.2.2	Screening .....	126
3.6.3	Testing.....	127
3.6.3.1	Nucleic acid amplification tests (NAATs).....	127
3.6.3.2	Performance of NAAT Tests.....	136
3.6.4	Market Opportunity Analysis .....	137
3.7	Tuberculosis.....	139
3.7.1	Mycobacteria.....	140
3.7.2	Diagnosis .....	142
3.7.2.1	Active tuberculosis .....	142
3.7.2.2	Latent tuberculosis.....	142
3.7.3	Epidemiology .....	143

3.7.4	Molecular Diagnostic Tests .....	145
3.7.5	Market Opportunity Analysis .....	146
3.8	MRSA - Methicillin-resistant Staphylococcus aureus .....	148
3.8.1	Diagnosis .....	148
3.8.2	FDA Approved Molecular Tests .....	149
3.8.3	Market Opportunity Analysis .....	150
3.9	VRE - Vancomycin-resistant Enterococcus.....	152
3.9.1	FDA Approved MDx Tests for VRE.....	153
3.9.2	Market Opportunity Analysis .....	154
3.10	Blood Screening .....	155
3.10.1	Collection and Testing .....	155
3.10.2	FDA Approved Multiplex Assays.....	156
3.10.3	Market Opportunity Analysis .....	158
3.11	COVID-19 .....	159
3.11.1	Signs and symptoms.....	160
3.11.2	Transmission.....	162
3.11.3	Diagnosis .....	163
3.11.4	Prevention.....	165
3.11.5	Management .....	166
3.11.6	Prognosis .....	167
3.12	Pandemic Diagnostics.....	168
3.12.1	Risk Management – Spark and Spread .....	168
3.12.2	Dx Technology – Nucleic Acid Based.....	170
3.12.3	Dx Technology - Immunoassay & Serology .....	171



3.12.4	Time to Market and Preparedness Issues .....	172
3.12.5	Unrecognized Role of Multiplex in Pandemic Mangement.....	172
4	Industry Overview.....	174
4.1	Players in a Dynamic Market.....	175
4.1.1	Academic Research Lab .....	176
4.1.2	Diagnostic Test Developer.....	176
4.1.3	Instrumentation Supplier .....	176
4.1.4	Distributor and Reagent Supplier .....	177
4.1.5	Independent Testing Lab.....	177
4.1.6	Public National/regional lab .....	178
4.1.7	Hospital lab .....	178
4.1.8	Physician Office Labs and Clinics .....	179
4.1.9	Audit Body .....	179
4.1.10	Certification Body.....	179
4.2	The Clinical Laboratory Market Segments .....	181
4.2.1	Traditional Market Segmentation.....	181
4.2.2	Laboratory Focus and Segmentation.....	183
4.3	Industry Structure.....	185
4.3.1	Hospital Testing Share .....	185
4.3.2	Economies of Scale.....	185
4.3.2.1	Hospital vs. Central Lab.....	186
4.3.3	Physician Office Lab's.....	187
4.3.4	Physician's and POCT .....	187
5	Profiles of Key MDx Companies .....	189

5.1	Abacus Diagnostica .....	190
5.2	Abbott Diagnostics .....	191
5.3	Accelerate Diagnostics .....	193
5.4	Ador Diagnostics .....	194
5.5	Akonni Biosystems .....	195
5.6	Alveo Technologies.....	196
5.7	Applied BioCode .....	197
5.8	Aus Diagnostics .....	199
5.9	Beckman Coulter Diagnostics.....	200
5.10	Becton, Dickinson and Company .....	201
5.11	Binx Health .....	203
5.12	Biocartis.....	204
5.13	bioMérieux Diagnostics.....	205
5.14	Bio-Rad Laboratories, Inc.....	208
5.15	Bosch Healthcare Solutions GmbH .....	210
5.16	Cepheid (now Danaher) .....	211
5.17	Chembio .....	212
5.18	Co Diagnostics .....	213
5.19	Credo Diagnostics Biomedical .....	214
5.20	Cue Health.....	215
5.21	Curetis N.V. / Curetis GmbH .....	216
5.22	Diagenode Diagnostics .....	217
5.23	Diascopic .....	218
5.24	Diasorin S.p.A. ....	219

5.25	Eiken Chemical .....	220
5.26	Enzo Life Sciences, Inc. ....	221
5.27	Eurofins Scientific .....	223
5.28	Fluxergy .....	225
5.29	Fulgent Genetics .....	226
5.30	Fusion Genomics. ....	227
5.31	Genedrive.....	229
5.32	Genetic Signatures.....	230
5.33	GenMark Dx.....	231
5.34	Grifols.....	233
5.35	Hibergene Diagnostics.....	234
5.36	Hologic .....	235
5.37	Illumina .....	237
5.38	Immunexpress.....	238
5.39	Inflammatix .....	239
5.40	Invetech.....	240
5.41	Janssen Diagnostics .....	241
5.42	Karius .....	242
5.43	Lexagene .....	243
5.44	LightDeck Diagnostics .....	244
5.45	Luminex Corp .....	245
5.46	Lumos Diagnostics.....	247
5.47	Mammoth Biosciences .....	248
5.48	Maxim Biomedical .....	249

5.49	Meridian Bioscience.....	250
5.50	Mesa Biotech.....	252
5.51	Millipore Sigma .....	253
5.52	Mindray .....	254
5.53	Mobidiag .....	255
5.54	Nanomix.....	256
5.55	Operon.....	257
5.56	Oxford Nanopore Technologies .....	258
5.57	Panagene.....	259
5.58	Perkin Elmer.....	260
5.59	Primerdesign .....	262
5.60	Prominex .....	263
5.61	Qiagen Gmbh .....	264
5.62	Quantumdx .....	266
5.63	Quidel.....	267
5.64	Roche Molecular Diagnostics .....	269
5.65	Saw Diagnostics .....	271
5.66	Seegene.....	272
5.67	Siemens Healthineers .....	273
5.68	Sona Nanotech .....	276
5.69	SpeeDx.....	277
5.70	T2 Biosystems.....	278
5.71	Thermo Fisher Scientific Inc.....	279
5.72	Veramarx .....	281

5.73	Veredus Laboratories.....	282
5.74	Vir.....	283
5.75	XCR Diagnostics .....	284
6	Market Trends .....	285
6.1	Factors Driving Growth .....	286
6.1.1	New Genotypes Creating New Markets .....	287
6.1.2	Aging Population a Boon for All Diagnostics .....	287
6.1.3	Developing World Driving ID Dx Growth.....	288
6.1.4	Point of Care – Why Centralization is Losing Steam .....	288
6.1.5	Self Testing.....	289
6.1.6	The Need for Speed .....	289
6.1.7	The COVID Pandemic.....	289
6.2	Factors Limiting Growth .....	290
6.2.1	Lower Costs.....	290
6.2.2	Infectious Disease is Declining .....	292
6.2.3	Wellness Hurts.....	292
6.2.4	Economic Growth improves Living Standards .....	292
6.3	Instrumentation and Automation .....	293
6.3.1	Instruments Key to Market Share .....	293
6.3.2	The Shrinking Machine .....	293
6.3.3	Multiplex, Point of Care and The Speed Factor.....	293
6.4	Diagnostic Technology Development .....	295
6.4.1	The Sepsis Testing Market – A New Direction? .....	296
6.4.2	POCT/Self Testing as a Disruptive Force .....	296

6.4.3	The Genetics Play – One Test for All Known Infections.....	297
6.4.4	Antibiotic Resistance Genes – Simplifying Diagnostics.....	297
7	Molecular Dx – Infectious Disease Recent Developments .....	298
7.1	Recent Developments – Importance and How to Use This Section .....	299
7.1.1	Importance of These Developments .....	299
7.1.2	How to Use This Section.....	299
7.2	BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform .....	299
7.3	Talis Biomedical Discusses Point-of-Care.....	303
7.4	Roche to Acquire GenMark Diagnostics for \$1.8B .....	307
7.5	Pandemic Pushes Handheld qPCR Devices Closer to Commercialization.....	308
7.6	Hologic to Acquire Mobidiag .....	316
7.7	Lucira Health Focuses on User Friendly Approach to Home Testing .....	317
7.8	Infectious Disease Dx Firm Talis Biomedical Raises \$254M in IPO.....	323
7.9	Fluidigm Plans 'Durable' Diagnostics, Clinical Business.....	323
7.10	Thermo Fisher Scientific to Acquire Mesa Biotech for Up to \$550M .....	327
7.11	Mammoth Biosciences Developing Pathogen Detection Tech .....	328
7.12	Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests .....	331
7.13	Scanogen Developing 90 Minute Infection Test.....	336
7.14	Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection .....	339
7.15	FDA Provides Self Testing SARS-CoV-2 EAU Guidance .....	342
7.16	Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic ....	344
7.17	Genetic Signatures Gets CE Mark for Coronavirus Molecular Test .....	345
7.18	Qiagen Respiratory Panel with Coronavirus Receives CE Mark.....	346
7.19	Lumos Diagnostics Closes \$15M Series A Funding .....	347

7.20	Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay .....	348
7.21	New Genomic Tests Diagnose Deadly Infections Faster .....	349
7.22	Biotia Raises \$2.4M Seed Round .....	354
7.23	STDs resurge in US .....	356
7.24	Ares Genetics signs R&D agreement with leading global IVD corporation.....	357
7.25	Cell-Free DNA Used for Infectious Disease Testing .....	358
7.26	One BioMed Raises \$5M .....	359
8	The Global Market for Molecular Diagnostics at the Point of Care .....	361
8.1	Global Market Overview by Country .....	362
8.1.1	Table – Global Market by Country.....	362
8.1.2	Chart - Global Market by Country .....	363
8.2	Global Market by Application - Overview.....	364
8.2.1	Table – Global Market by Application .....	364
8.2.2	Chart – Global Market by Application – Base/Final Year Comparison .....	365
8.2.3	Chart – Global Market by Application – Base Year .....	366
8.2.4	Chart – Global Market by Application – End Year .....	367
8.2.5	Chart – Global Market by Application – Share by Year.....	368
8.2.6	Chart – Global Market by Application – Segments Growth.....	369
8.3	Global Market by Technology - Overview.....	370
8.3.1	Table – Global Market by Technology .....	370
8.3.2	Chart – Global Market by Technology – Base/Final Year Comparison .....	371
8.3.3	Chart – Global Market by Technology – Base Year .....	372
8.3.4	Chart – Global Market by Technology – End Year .....	373
8.3.5	Chart – Global Market by Technology – Share by Year.....	374

8.3.6	Chart – Global Market by Technology – Segments Growth.....	375
8.4	Global Market by Place - Overview .....	376
8.4.1	Table – Global Market by Place.....	376
8.4.2	Chart – Global Market by Place – Base/Final Year Comparison .....	377
8.4.3	Chart – Global Market by Place – Base Year.....	378
8.4.4	Chart – Global Market by Place – End Year .....	379
8.4.5	Chart – Global Market by Place – Share by Year.....	380
8.4.6	Chart – Global Market by Place – Segments Growth .....	381
8.5	Global Market by Product - Overview .....	382
8.5.1	Table – Global Market by Product.....	382
8.5.2	Chart – Global Market by Product – Base/Final Year Comparison.....	383
8.5.3	Chart – Global Market by Product – Base Year.....	384
8.5.4	Chart – Global Market by Product – End Year .....	385
8.5.5	Chart – Global Market by Product – Share by Year.....	386
8.5.6	Chart – Global Market by Product – Segments Growth .....	387
9	Global MDx at the Point of Care Markets – By Application .....	388
9.1	Covid - 19.....	389
9.1.1	Table Covid - 19 – by Country .....	389
9.1.2	Chart - Covid - 19 Growth .....	390
9.2	Respiratory Infectious Disease.....	391
9.2.1	Table Respiratory Infectious Disease – by Country .....	391
9.2.2	Chart - Respiratory Infectious Disease Growth .....	392
9.3	Gastrointestinal Infectious Disease .....	393
9.3.1	Table Gastrointestinal Infectious Disease – by Country.....	393



9.3.2	Chart - Gastrointestinal Infectious Disease Growth .....	394
9.4	Sexually Transmitted Disease.....	395
9.4.1	Table Sexually Transmitted Disease – by Country .....	395
9.4.2	Chart - Sexually Transmitted Disease Growth .....	396
9.5	Other Application .....	396
9.5.1	Table Other Application – by Country.....	396
9.5.2	Chart - Other Application Growth .....	397
10	Global MDx Markets at the Point of Care – by Technology.....	399
10.1	PCR.....	400
10.1.1	Table PCR – by Country .....	400
10.1.2	Chart - PCR Growth.....	401
10.2	NGS/Probe.....	402
10.2.1	Table NGS/Probe – by Country .....	402
10.2.2	Chart - NGS/Probe Growth.....	403
10.3	Other Technology .....	404
10.3.1	Table Other Technology – by Country.....	404
10.3.2	Chart - Other Technology Growth .....	405
11	Global MDx at the Point of Care Markets – by Place .....	406
11.1	Hospital Point of Care .....	407
11.1.1	Table Hospital Point of Care – by Country .....	407
11.1.2	Chart - Hospital Point of Care Growth.....	408
11.2	Clinic or Physician Office Lab.....	409
11.2.1	Table Clinic or Physician Office Lab – by Country .....	409
11.2.2	Chart - Clinic or Physician Office Lab Growth .....	410

11.3	Seniors Facility .....	411
11.3.1	Table Seniors Facility – by Country .....	411
11.3.2	Chart – Seniors Facility Growth .....	412
11.4	Other Place .....	413
11.4.1	Table Other Place– by Country .....	413
11.4.2	Chart – Other Place Growth.....	414
12	Global MDx at the Point of Care Markets – by Product .....	415
12.1	Instrument .....	416
12.1.1	Table Instrument – by Country .....	416
12.1.2	Chart - Instrument Growth .....	417
12.2	Cartridge.....	418
12.2.1	Table Cartridge – by Country .....	418
12.2.2	Chart - Cartridge Growth .....	419
12.3	Other Product.....	420
12.3.1	Table Other Product – by Country .....	420
12.3.2	Chart – Other Product Growth.....	421
13	Appendices.....	422
13.1	United States Medicare System: 2021 Clinical Laboratory Fees Schedule .....	423

## Table of Tables

Table 1 Classification of HIV Species.....	44
Table 2 HIV Tests - CMS Codes & Prices .....	67
Table 3 Current HIV Molecular Tests and Instruments Used.....	68
Table 4 HBV Tests - CMS Codes & Prices .....	79
Table 5 HCV Tests - CMS Codes & Prices .....	87
Table 6 HPV Clearance Rates .....	93
Table 7 HPV Tests - CMS Codes & Prices.....	98
Table 8 HPV Tests, Technology, Types .....	99
Table 9 Types of Influenza Tests .....	111
Table 10 Influenza Tests - CMS Codes & Prices.....	114
Table 11 FDA Cleared Molecular Assays for Influenza .....	115
Table 12 FDA Cleared NAAT CTGC Tests .....	129
Table 13 CTGC NAAT Target Sequences and Possible False Reactions .....	133
Table 14 CTGC Tests - CMS Codes & Prices.....	138
Table 15 FDA Approved MDx Tests for Tuberculosis .....	145
Table 16 Tuberculosis Tests - CMS Codes & Prices.....	146
Table 17 FDA Approved Tests for MRSA .....	149
Table 18 MRSA Tests - CMS Codes & Prices .....	151
Table 19 FDA Approved Tests for VRE .....	153
Table 20 VRE Tests - CMS Codes & Prices .....	154

Table 21 FDA Approved Multiplex Assays .....	156
Table 22 Characteristics of Coronavirus Pandemic Infections .....	159
Table 23 COVID-19 Symptoms.....	161
Table 24 Market Players by Type .....	175
Table 25 Clinical Laboratory Departments and Segments .....	182
Table 26 Laboratory Management Focus – Different Approaches .....	183
Table 27 Key Segmentation Variables Going Forward.....	184
Table 28 Five Factors Driving Growth .....	286
Table 29 Four Factors Limiting Growth .....	290
Table 30 Key Diagnostic Laboratory Technology Trends .....	295
Table 31 - Global Market by Region .....	362
Table 32 Global Market by Application.....	364
Table 33 Global Market by Technology .....	370
Table 34 Global Market by Place.....	376
Table 35 Global Market by Product.....	382
Table 36 Covid - 19 by Country .....	389
Table 37 Respiratory Infectious Disease by Country .....	391
Table 38 Gastrointestinal Infectious Disease by Country.....	393
Table 39 Sexually Transmitted Disease by Country .....	395
Table 40 Other Application by Country.....	396
Table 41 PCR by Country .....	400
Table 42 NGS/Probe by Country .....	402
Table 43 Other Technology by Country.....	404
Table 44 Hospital Point of Care by Country .....	407

Table 45 Clinic or Physician Office Lab by Country .....	409
Table 46 Seniors Facility by Country .....	411
Table 47 Other Place by Country .....	413
Table 48 Instrument by Country .....	416
Table 49 Cartridge by Country .....	418
Table 50 Other Product by Country .....	420
Table 51 2021 Clinical Lab Fee Schedule .....	423

## Table of Figures

Figure 1 Map - Global Healthcare Spending Per Capita.....	39
Figure 2 The Lab Test Pie - Wholesale vs. Retail.....	40
Figure 3 HIV Virion.....	45
Figure 4 Diagram of the HIV Replication Cycle.....	49
Figure 5 The Structure of the HBV Virus.....	73
Figure 6 Hepatitis B Replication.....	74
Figure 7 Structure of the HCV Virus.....	81
Figure 8 HCV Replication Cycle.....	84
Figure 9 Structure of the Influenza Virion.....	107
Figure 10 Influenza Replication.....	108
Figure 11 Scanning Electronmicrograph of Tuberculosis.....	141
Figure 12 Percentage of World Population Over 65.....	288
Figure 13 Chart Infectious Disease Decline.....	291
Figure 14 Global Market Shares Chart.....	363
Figure 15 Global Market by Application - Base vs. Final.....	365
Figure 16 Global Market by Application Base Year.....	366
Figure 17 Global Market by Application End Year.....	367
Figure 18 Application Share by Year.....	368
Figure 19 Application Segments Growth.....	369
Figure 20 Global Market by Technology - Base vs. Final.....	371
Figure 21 Global Market by Technology Base Year.....	372

Figure 22 Global Market by Technology End Year .....	373
Figure 23 Technology Share by Year.....	374
Figure 24 Technology Segments Growth .....	375
Figure 25 Global Market by Place - Base vs. Final.....	377
Figure 26 Global Market by Place Base Year .....	378
Figure 27 Global Market by Place End Year .....	379
Figure 28 Place Share by Year.....	380
Figure 29 Place Segments Growth .....	381
Figure 30 Global Market by Product - Base vs. Final.....	383
Figure 31 Global Market by Product Base Year .....	384
Figure 32 Global Market by Product End Year.....	385
Figure 33 Product Share by Year .....	386
Figure 34 Product Segments Growth .....	387
Figure 35 Covid - 19 Growth .....	390
Figure 36 Other Infectious Disease Diagnostics Growth .....	392
Figure 37 Gastrointestinal Infectious Disease Growth .....	394
Figure 38 Sexually Transmitted Disease Growth .....	396
Figure 39 Other Application Growth.....	398
Figure 40 PCR Growth .....	401
Figure 41 NGS/Probe Growth .....	403
Figure 42 Other Technology Growth.....	405
Figure 43 Hospital Point of Care Growth.....	408
Figure 44 Clinic or Physician Office Lab Growth .....	410
Figure 45 Seniors Facility Growth .....	412

Figure 46 Other Place Growth ..... 414

Figure 47 Instrument Growth ..... 417

Figure 48 Cartridge Growth ..... 419

Figure 49 Other Product Growth ..... 421